Two gout experts debated whether first-line urate-lowering therapy should consist of a xanthine oxidase inhibitor or should ...

In gout, used in the study by De Vera et al. as a clinical surrogate for hyperuricemia, which mechanism is more responsible for the apparent increase in cardiovascular risk?

Probenecid is indicated for the management of hyperuricemia associated with chronic gout. By preventing the reabsorption of serum uric acid in the proximal tubule, probenecid corrects ...

Inflammatory arthritis in patients with gout can usually be treated with drugs that counter hyperuricemia. Treatment fails in some patients, however, so a second-line therapy is desirable.

A lack of exercise can also contribute to gout, as can chronic conditions like high blood pressure and diabetes. A genetic ...

Gout is a type of inflammatory arthritis that affects over 9 million American adults. It results from hyperuricemia (high ...

TOKYO, Dec 11, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has received approval for “URECE®” (brand name in China: “优乐思®”, generic name: dotinurad) from the National Medical ...

Gout is a type of inflammatory arthritis that develops when the body has high uric acid levels, known as hyperuricemia. Gout often affects the big toe but can also affect other joints, including ...

Hyperuricemia (HU) is a global health concern ... such as cardiovascular diseases (CVDs), gout, metabolic syndrome (MS), renal dysfunction, and neurodegenerative diseases. The review emphasizes ...

Ltd.”) of class 1 innovative drug ABP-671 for the treatment of gout and hyperuricemia (the “Product”). In accordance with the Agreement, the Group is entitled to an exclusive commercialization right ...

No new safety concerns with dotinurad were observed. “URECE” is a new therapeutic medicine for gout and hyperuricemia discovered by FUJI YAKUHIN. It suppresses uric acid reabsorption and ...

Ltd (hereinafter referred to as "Atom Therapeutics”, formerly named as "Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.”) of class 1 innovative drug ABP-671 for the treatment of gout and ...